RSV is the most common cause of hospitalization in babies, but Sanofi is one of a few companies producing a shot that can ...

Moderna's shares fell 2.3% on Friday on concerns about whether a new CDC advisory panel would back the use of the company's ...

A U.S. government scientist who oversees the team responsible for collecting data on COVID-19 and RSV hospitalizations used ...

The U.S. Centers for Disease Control and Prevention panel of vaccine experts will vote on shots for respiratory syncytial ...

A senior scientist at the US CDC has resigned, warning that changes in leadership may weaken the country’s vaccine program.

The RSV shot, mRESVIA, secured U.S. approval on Thursday for expanded use in at-risk adults aged 18 to 59 years, but needs ...

A Centers for Disease Control and Prevention official who led the agency's network to study hospitalization trends from ...

A scientist in charge of Covid-19 and respiratory syncytial virus data has abruptly resigned, telling colleagues she doesn’t ...

Kennedy Jr. in the country's top health position, use of a long-approved vaccine against measles, mumps, rubella, and ...

The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...